サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1401005

遅発性ジスキネジア（TD）治療薬市場：治療タイプ別、薬剤別、流通別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2023年～2030年

Tardive Dyskinesia Therapeutics Market, By Treatment Type, By Drug, By Distribution, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日: | 発行: AnalystView Market Insights | ページ情報: 英文 300 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
遅発性ジスキネジア（TD）治療薬市場：治療タイプ別、薬剤別、流通別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2023年～2030年
出版日: 2023年12月17日
発行: AnalystView Market Insights
ページ情報: 英文 300 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

遅発性ジスキネジア（TD）治療薬の市場規模は2022年に23億4,000万米ドルとなり、2023年から2030年にかけてCAGR 9.1%で拡大すると予想されます。

遅発性ジスキネジア（TD）治療薬市場-市場力学

遅発性ジスキネジア（TD）が患者の健康に与える影響に対する認識の高まりが市場需要を促進

社会や医療関係者の理解が深まるにつれ、遅発性ジスキネジア（TD）の症状の早期発見と治療が重視されるようになっています。このため、製薬会社はアンメット・メディカル・ニーズに対応するため、VMAT2阻害剤を含む新規治療薬の研究開発に取り組んでいます。さらに、規制当局がTD治療薬の迅速な承認取得を支持していることは、個人に安全で効果的な選択肢を提供する必要性を強調しています。TD治療の選択肢を開発するための協力的な努力は、患者のQOLを高め、この運動障害の影響を軽減したいという願望によって推進されています。

遅発性ジスキネジア（TD）治療薬市場-主な洞察

弊社のリサーチアナリストの分析によると、遅発性ジスキネジア（TD）治療薬の世界市場は、予測期間（2023-2030年）にCAGR 約9.1%で成長すると予測されています。

遅発性ジスキネジア（TD）治療薬業界は、患者の幸福に影響を与える疾患であるという認識の高まりにより、著しい速度で成長すると予測されます。

治療タイプ別では、薬物療法が2022年に最大の市場シェアを占めています。

薬剤別では、ドイテトラベナジンが2022年の主要タイプです。

地域別では、北米が2022年の収益でリードしています。

遅発性ジスキネジア（TD）治療薬市場-セグメンテーション分析：

遅発性ジスキネジア（TD）治療薬の世界市場は、治療タイプ、薬剤、流通、地域に基づいて区分されます。

市場は治療タイプによって2つに分類されます：薬物療法と非薬物療法です。市場を独占しているのは薬物療法です。遅発性ジスキネジア（TD）の治療では、薬物療法の需要が高いです。TDの症状をコントロールするために、患者はVMAT2阻害薬や抗精神病薬などの効果的な薬剤を求めています。製薬業界は、遅発性ジスキネジア（TD）治療におけるより良い薬理学的選択肢に対するニーズの高まりに応えるべく、安全でオーダーメイドの医薬品創出に注力しています。

市場は薬剤によって3つのカテゴリーに分けられる：ドイテトラベナジン、バルベナジン、その他。ドイテトラベナジン分野は市場を独占しており、予測期間中もその優位性を維持するとみられます。VMAT2阻害剤であるドイテトラベナジンは、遅発性ジスキネジア（TD）の治療薬として普及しつつあります。ドパミンレベルを調節するその能力は、遅発性ジスキネジア（TD）の症状を効率的に治療する上で有望です。deutetrabenazineの需要は、患者やヘルスケア専門家が新たな解決策を求める中、TD管理における有益な治療オプションとしての可能性を浮き彫りにしています。

遅発性ジスキネジア（TD）治療薬市場-地理的洞察

地理的には、北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの各地域に広がっています。これらの地域は、ビジネスを展開する国によってさらに分けられます。北米の遅発性ジスキネジア（TD）治療薬市場には、さまざまな変数が影響しています。この地域は抗精神病薬を服用している人口が多く、TDのリスクを高めています。医療従事者や患者の間でTDの影響に対する認識が高まっているため、適切な治療法の開発が必要とされています。規制当局の承認は、新薬の利用を促進します。確立された製薬業界と広範なヘルスケアシステムは、TD治療薬の研究開発および普及を支援しています。抗精神病薬による治療を必要とする精神疾患の頻度が増加していることから、TDへの対応の必要性が強調され、北米はTDの症状を抑制・軽減することを目的とした新薬にとって重要な市場となっています。

目次

第1章 遅発性ジスキネジア（TD）治療薬市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 遅発性ジスキネジア（TD）治療薬の主要な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 今後の市場動向

第4章 遅発性ジスキネジア（TD）治療薬業界の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 規制枠組みの分析

第5章 遅発性ジスキネジア（TD）治療薬市場：COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19以後の影響分析

第6章 遅発性ジスキネジア（TD）治療薬市場情勢

  • 遅発性ジスキネジア（TD）治療薬市場シェア分析、2022年
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 遅発性ジスキネジア（TD）治療薬市場：治療タイプ別

  • 概要
    • 治療タイプ別のセグメントシェア分析
    • 薬物療法
    • 非薬物療法

第8章 遅発性ジスキネジア（TD）治療薬市場：薬剤別

  • 概要
    • 薬剤別のセグメントシェア分析
    • デュテトラベナジン
    • バルベナジン
    • その他

第9章 遅発性ジスキネジア（TD）治療薬市場：流通別

  • 概要
    • 流通別のセグメントシェア分析
    • 病院薬局
    • ドラッグストアおよび小売薬局
    • オンライン薬局

第10章 遅発性ジスキネジア（TD）治療薬市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東とアフリカ
    • 概要
    • 中東およびアフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析：遅発性ジスキネジア（TD）治療薬産業

  • 競合ダッシュボード
  • 企業プロファイル
    • Neurocrine Biosciences, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Bausch Health Companies Inc.
    • Sunovion Pharmaceuticals Inc.
    • Teikoku Pharma USA, Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • Neurolixis, Inc.
    • Retrophin, Inc.
    • NeuroSearch A/S
    • Abide Therapeutics, Inc.
    • Cynapsus Therapeutics Inc.
    • Ichor Medical Systems
    • Reviva Pharmaceuticals Inc.
    • Acorda Therapeutics, Inc.
    • Adamas Pharmaceuticals, Inc.

第12章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Tardive Dyskinesia Therapeutics Market: Treatment Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Treatment Type
  • TABLE Global Tardive Dyskinesia Therapeutics Market, by Treatment Type 2018-2030 (USD Million)
  • TABLE Tardive Dyskinesia Therapeutics Market: Drug Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug
  • TABLE Global Tardive Dyskinesia Therapeutics Market, by Drug 2018-2030 (USD Million)
  • TABLE Tardive Dyskinesia Therapeutics Market: Distribution Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution
  • TABLE Global Tardive Dyskinesia Therapeutics Market, by Distribution 2018-2030 (USD Million)
  • TABLE Tardive Dyskinesia Therapeutics Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Tardive Dyskinesia Therapeutics Market, by Region 2018-2030 (USD Million)
  • TABLE North America Tardive Dyskinesia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Tardive Dyskinesia Therapeutics Market, by Treatment Type, 2018-2030 (USD Million)
  • TABLE North America Tardive Dyskinesia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE North America Tardive Dyskinesia Therapeutics Market, by Distribution, 2018-2030 (USD Million)
  • TABLE Europe Tardive Dyskinesia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Tardive Dyskinesia Therapeutics Market, by Treatment Type, 2018-2030 (USD Million)
  • TABLE Europe Tardive Dyskinesia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Europe Tardive Dyskinesia Therapeutics Market, by Distribution, 2018-2030 (USD Million)
  • TABLE Asia Pacific Tardive Dyskinesia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Tardive Dyskinesia Therapeutics Market, by Treatment Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Tardive Dyskinesia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Asia Pacific Tardive Dyskinesia Therapeutics Market, by Distribution, 2018-2030 (USD Million)
  • TABLE Latin America Tardive Dyskinesia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Tardive Dyskinesia Therapeutics Market, by Treatment Type, 2018-2030 (USD Million)
  • TABLE Latin America Tardive Dyskinesia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Latin America Tardive Dyskinesia Therapeutics Market, by Distribution, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Tardive Dyskinesia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Tardive Dyskinesia Therapeutics Market, by Treatment Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Tardive Dyskinesia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Tardive Dyskinesia Therapeutics Market, by Distribution, 2018-2030 (USD Million)

List of Figures

  • FIGURE Tardive Dyskinesia Therapeutics Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Treatment Type segment market share analysis, 2022 & 2030
  • FIGURE Treatment Type segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Drug segment market share analysis, 2022 & 2030
  • FIGURE Drug segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Distribution segment market share analysis, 2022 & 2030
  • FIGURE Distribution segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022 & 2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Tardive Dyskinesia Therapeutics Market share and leading players, 2022
  • FIGURE Europe Tardive Dyskinesia Therapeutics Market share and leading players, 2022
  • FIGURE Asia Pacific Tardive Dyskinesia Therapeutics Market share and leading players, 2022
  • FIGURE Latin America Tardive Dyskinesia Therapeutics Market share and leading players, 2022
  • FIGURE Middle East and Africa Tardive Dyskinesia Therapeutics Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Tardive Dyskinesia Therapeutics Market share analysis by country, 2022
  • FIGURE Germany Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Tardive Dyskinesia Therapeutics Market share analysis by country, 2022
  • FIGURE India Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Tardive Dyskinesia Therapeutics Market share analysis by country, 2022
  • FIGURE Brazil Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Tardive Dyskinesia Therapeutics Market share analysis by country, 2022
  • FIGURE Saudi Arabia Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Tardive Dyskinesia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
目次
Product Code: ANV1969

REPORT HIGHLIGHT

Tardive Dyskinesia Therapeutics Market size was valued at USD 2,340 Million in 2022, expanding at a CAGR of 9.1% from 2023 to 2030.

Tardive Dyskinesia (TD) treatments are medical procedures that try to relieve the uncontrollable and irregular movements that might occur as a consequence of long-term usage of certain antipsychotic medicines. These therapy techniques include pharmaceutical therapies such as antipsychotic adjustments or VMAT2 inhibitors, which aid in the management of TD symptoms. Non-pharmacological treatments such as behavioral counseling and deep brain stimulation can additionally be used. The purpose of TD therapies is to reduce or eliminate the disruptive motor manifestations of TD, therefore enhancing patients' general level of life and giving respite from the sometimes-upsetting symptoms of this medication-induced mobility disorder.

Tardive Dyskinesia Therapeutics Market- Market Dynamics

Increasing recognition of the condition's impact on patients' well-being to propel market demand

As public and medical professional understanding grows, there is a greater emphasis on early detection and treatment of TD symptoms. This encourages pharmaceutical companies to conduct novel therapeutic research and development, which includes VMAT2 inhibitors, to address unmet medical needs. Furthermore, regulatory authorities' support for expediting TD drug approval stresses the need to offer individuals safe and effective choices. The collaborative efforts to develop TD treatment options are driven by a desire to enhance patient's quality of life and reduce the effect of this movement disorder.

Tardive Dyskinesia Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global Tardive Dyskinesia Therapeutics market is estimated to grow annually at a CAGR of around 9.1% over the forecast period (2023-2030)

The Tardive Dyskinesia Therapeutics industry is projected to grow at a significant rate due to increasing recognition of the condition's impact on patients' well-being

Based on Treatment Type segmentation, Pharmacological Therapies was predicted to show maximum market share in the year 2022

Based on Drug segmentation, Deutetrabenazine was the leading type in 2022

On the basis of region, North America was the leading revenue generator in 2022

Tardive Dyskinesia Therapeutics Market- Segmentation Analysis:

The Global Tardive Dyskinesia Therapeutics Market is segmented on the basis of Treatment Type, Drug, Distribution, and Region.

The market is divided into two categories based on Treatment Type: Pharmacological Therapies, Non-pharmacological Therapies. The Pharmacological Therapies dominates the market. Pharmacological medications are in high demand in the treatment of Tardive Dyskinesia (TD). To control TD symptoms, patients seek effective drugs such as VMAT2 inhibitors and antipsychotic modifications. The pharmaceutical industry is focused on creating safe and tailored medicines to meet the rising need for better pharmacological choices in TD therapy.

The market is divided into three categories based on Drug: Deutetrabenazine, Valbenazine, Others. The Deutetrabenazine sector dominates the market and is likely to maintain its dominance during the forecast period. Deutetrabenazine, a VMAT2 inhibitor, is becoming more popular in the treatment of Tardive Dyskinesia (TD). Its capacity to modulate dopamine levels provides promise for efficiently treating TD symptoms. The demand for deutetrabenazine highlights its potential as a beneficial treatment option in TD management as patients and healthcare professionals seek novel solutions.

Tardive Dyskinesia Therapeutics Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. A variety of variables influence the market for Tardive Dyskinesia (TD) medicines in North America. The area has a large population on antipsychotic drugs, which raises the risk of TD. The growing awareness of the effects of TD among healthcare professionals and patients necessitates the development of appropriate therapies. Regulatory approval expedites the availability of novel medicines. The well-established pharmaceutical industry and extensive healthcare system assist TD medicinal research, development, and dissemination. The increased frequency of mental illnesses requiring antipsychotic treatment emphasises the need of addressing TD, making North America a critical market for novel medications targeted at controlling and reducing TD symptoms.

Tardive Dyskinesia Therapeutics Market- Competitive Landscape:

Key pharmaceutical participants in the Tardive Dyskinesia (TD) treatment landscape include Neurocrine Biosciences, Teva, and Bausch Health. These firms are at the forefront of VMAT2 inhibitors and antipsychotic modifications. Treatment effectiveness, safety profiles, and market penetration are all important factors in market competitiveness. The rivalry is shaped by clinical studies, governmental approvals, and marketing initiatives. Niche players concentrate on novel non-pharmacological techniques. Collaborations and collaborations foster innovative therapy research and development. The competitive climate is dynamic, with a rising patient population and increased awareness seeking to meet unmet requirements of TD patients and deliver effective solutions for controlling this complex movement condition.

Recent Developments:

In May 2023, During Tardive Dyskinesia Awareness Week Neurocrine Biosciences, Inc. highlighted its continuing support for raising awareness about the prevalence, impact, and relevance of screening for tardive dyskinesia (TD). TD is an involuntary movement condition caused by long-term use of certain mental health medications (antipsychotics) intended to treat depression, schizophrenia, bipolar disorder,and schizoaffective disorder.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET KEY PLAYERS

  • Neurocrine Biosciences, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bausch Health Companies Inc.
  • Sunovion Pharmaceuticals Inc.
  • Teikoku Pharma USA, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Neurolixis, Inc.
  • Retrophin, Inc.
  • NeuroSearch A/S
  • Abide Therapeutics, Inc.
  • Cynapsus Therapeutics Inc.
  • Ichor Medical Systems
  • Reviva Pharmaceuticals Inc.
  • Acorda Therapeutics, Inc.
  • Adamas Pharmaceuticals, Inc.

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY TREATMENT TYPE

  • Pharmacological Therapies
  • Non-pharmacological Therapies

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY DRUG

  • Deutetrabenazine
  • Valbenazine
  • Others

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY DISTRIBUTION

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Tardive Dyskinesia Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Tardive Dyskinesia Therapeutics Market Snippet by Treatment Type
    • 2.1.2. Tardive Dyskinesia Therapeutics Market Snippet by Drug
    • 2.1.3. Tardive Dyskinesia Therapeutics Market Snippet by Distribution
    • 2.1.4. Tardive Dyskinesia Therapeutics Market Snippet by Country
    • 2.1.5. Tardive Dyskinesia Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Tardive Dyskinesia Therapeutics Key Market Trends

  • 3.1. Tardive Dyskinesia Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Tardive Dyskinesia Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Tardive Dyskinesia Therapeutics Market Opportunities
  • 3.4. Tardive Dyskinesia Therapeutics Market Future Trends

4. Tardive Dyskinesia Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Tardive Dyskinesia Therapeutics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Tardive Dyskinesia Therapeutics Market Landscape

  • 6.1. Tardive Dyskinesia Therapeutics Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Tardive Dyskinesia Therapeutics Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2022 & 2030 (%)
    • 7.1.2. Pharmacological Therapies
    • 7.1.3. Non-pharmacological Therapies

8. Tardive Dyskinesia Therapeutics Market - By Drug

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug, 2022 & 2030 (%)
    • 8.1.2. Deutetrabenazine
    • 8.1.3. Valbenazine
    • 8.1.4. Others

9. Tardive Dyskinesia Therapeutics Market - By Distribution

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution, 2022 & 2030 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Drug Stores & Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Tardive Dyskinesia Therapeutics Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Tardive Dyskinesia Therapeutics Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Tardive Dyskinesia Therapeutics Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Tardive Dyskinesia Therapeutics Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Tardive Dyskinesia Therapeutics Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Tardive Dyskinesia Therapeutics Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Tardive Dyskinesia Therapeutics Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Neurocrine Biosciences, Inc.
    • 11.2.2. Teva Pharmaceutical Industries Ltd.
    • 11.2.3. Bausch Health Companies Inc.
    • 11.2.4. Sunovion Pharmaceuticals Inc.
    • 11.2.5. Teikoku Pharma USA, Inc.
    • 11.2.6. Otsuka Pharmaceutical Co., Ltd.
    • 11.2.7. Neurolixis, Inc.
    • 11.2.8. Retrophin, Inc.
    • 11.2.9. NeuroSearch A/S
    • 11.2.10. Abide Therapeutics, Inc.
    • 11.2.11. Cynapsus Therapeutics Inc.
    • 11.2.12. Ichor Medical Systems
    • 11.2.13. Reviva Pharmaceuticals Inc.
    • 11.2.14. Acorda Therapeutics, Inc.
    • 11.2.15. Adamas Pharmaceuticals, Inc.

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us